Leavell Investment Management Inc. Invests $340,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Leavell Investment Management Inc. bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 10,000 shares of the company's stock, valued at approximately $340,000.

Several other hedge funds have also recently added to or reduced their stakes in CRSP. T. Rowe Price Investment Management Inc. increased its holdings in CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after acquiring an additional 1,074,238 shares in the last quarter. Capital International Investors boosted its stake in shares of CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock worth $344,145,000 after purchasing an additional 816,789 shares during the last quarter. Baker BROS. Advisors LP boosted its stake in shares of CRISPR Therapeutics by 55.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock worth $51,483,000 after purchasing an additional 464,936 shares during the last quarter. Norges Bank acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth about $17,458,000. Finally, Contrarius Group Holdings Ltd acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth about $14,516,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider directly owned 6,068 shares of the company's stock, valued at approximately $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.30% of the company's stock.

CRISPR Therapeutics Price Performance

CRSP stock traded down $2.20 during midday trading on Friday, reaching $56.80. 2,883,963 shares of the company's stock traded hands, compared to its average volume of 1,947,528. The company has a market capitalization of $4.91 billion, a P/E ratio of -12.57 and a beta of 1.82. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $63.68. The business has a 50-day moving average price of $42.52 and a two-hundred day moving average price of $41.28.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. CRISPR Therapeutics's revenue was up 71.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.43) EPS. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRSP has been the topic of several analyst reports. The Goldman Sachs Group decreased their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Finally, JMP Securities reissued a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.